This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read INmune Bio’s 8K filing here.
About INmune Bio
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
See Also
- Five stocks we like better than INmune Bio
- Low PE Growth Stocks: Unlocking Investment Opportunities
- These Stocks Missed on Earnings, But Will Rebound Next Quarter
- What is the Australian Securities Exchange (ASX)
- With Policy Shifts in Play, Are Crypto Stocks Worth Another Look?
- Quiet Period Expirations Explained
- Why Waste Management Stock Is a Top Defensive Play Now
